Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
CC transcript
Appointed director

Merck & Co., Inc. (MRK) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/25/2021 GN SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Pandion Therapeutics, Inc. Buyout
09/08/2020 GN Biopharma Leaders Unite to Stand with Science
08/11/2020 GN Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2020
01/28/2020 GN BriaCell's Clinical Data Accepted to be Presented at the Annual Symposium of Society of Surgical Oncology 2020 in Boston
01/13/2020 GN BriaCell Provides Update on Remarkable Responder
01/09/2020 GN BriaCell Outlines New High Responding Patient Group ‘Biomarker' Based on Cancer Grade
01/02/2020 GN BriaCell Completes Share Consolidation
12/20/2019 GN NewLink Genetics Announces FDA Approval of Ebola Vaccine V920 (ERVEBO®)
12/17/2019 GN BriaCell to Present at Biotech Showcase™ 2020 in San Francisco
12/13/2019 GN BriaCell Announces Clinical Data as Presented at the 2019 San Antonio Breast Cancer Symposium®
11/12/2019 GN BriaCell to Present Clinical Findings at the 2019 San Antonio Breast Cancer Symposium® December 12th and 13th
10/24/2019 GN BriaCell Announces Voting Results of the Special Meeting of Shareholders
10/08/2019 GN BriaCell Therapeutics Corp. to File Amendment to Management Information Circular
10/01/2019 GN Note from Chairman of BriaCell Therapeutics – October is Breast Cancer Awareness Month
09/25/2019 GN BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special ‘Targeted Immunotherapy' Issue in Prestigious Journals
09/20/2019 GN BriaCell Announces Private Placement of up to $600,000
09/19/2019 GN BriaCell Announces Public Disclosure: Remarkable Responder in Combination Study of Lead Candidate with KEYTRUDA®
09/16/2019 GN BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia
09/09/2019 GN BriaCell Announces Closing of Upsized Non-Brokered Private Placement of $846,301.49
08/27/2019 GN BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019
08/12/2019 GN BriaCell Appoints Richard J. Berman to Board of Directors
07/23/2019 GN BriaCell Announces $350,000 Equity Investment by Board of Directors
04/23/2019 GN BriaCell Announces Publication at American Society of Clinical Oncology (ASCO) Meeting and Presentation at Precision Breast Cancer Summit in Boston
04/03/2019 GN BriaCell's Lead Candidate Combined With KEYTRUDA®: Strong Evidence of Rapid Additive or Synergistic Anti-Tumor Activity
04/02/2019 GN BriaCell Announces Clinical Trial Collaboration Agreement with Incyte
04/01/2019 GN BriaCell Announces Closing of Upsized & Oversubscribed Non-Brokered Private Placement of $2.97 Million
03/26/2019 GN BriaCell to Announce Early Efficacy Data of Lead Candidate in Combination with KEYTRUDA® at AACR Annual Meeting
03/07/2019 GN BriaCell Therapeutics Corp. Highlights Recent Clinical and Scientific Achievements in Exclusive Audio Interview with NetworkNewsWire
02/26/2019 GN BriaCell Announces C$500,000 Equity Investment by BriaCell Director
02/21/2019 GN SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Immune Design Corp. to Merck & Co., Inc. for $5.85 Per Share is Fair to Shareholders
02/20/2019 GN New Research: Key Drivers of Growth for DISH Network, Avon Products, Merck & Co., Laredo Petroleum, Health Insurance Innovations, and Bruker — Factors of Influence, Major Initiatives and Sustained Production
02/15/2019 GN Cerecor Announces CERC-301 Granted U.S. Patent
01/02/2019 GN BriaCell Announces Switch to Novel Frozen Formulation for Lead Cancer Drug Candidate, Upcoming Attendance at Biotech Showcase™ 2019 and Presentation at Keystone Symposia Conference
12/28/2018 GN Analysis: Positioning to Benefit within General Motors, RE/MAX, Genworth Financial, Merck & Co., Aerojet Rocketdyne, and Fluor — Research Highlights Growth, Revenue, and Consolidated Results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy